The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2023

Filed:

Jul. 14, 2020
Applicant:

Nantbio, Inc., Culver City, CA (US);

Inventors:

Patrick Soon-Shiong, Culver City, CA (US);

Kayvan Niazi, Culver City, CA (US);

Shiho Tanaka, Culver City, CA (US);

Jon Thomas Van Lew, Culver City, CA (US);

Clifford Anders Olson, Culver City, CA (US);

Philip T. Liu, Culver City, CA (US);

Assignee:

NantBio, Inc., Culver City, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 45/06 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/715 (2006.01); A61K 39/00 (2006.01); C07K 14/54 (2006.01);
U.S. Cl.
CPC ...
C07K 16/244 (2013.01); A61K 38/1793 (2013.01); A61K 38/2086 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/545 (2013.01); C07K 14/5443 (2013.01); C07K 14/7155 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01);
Abstract

Compositions, methods, and uses of recombinant IL-8 antibody, fragment thereof or single chain variable fragment (scFv) having high affinity to IL-8 to target tumor-expressed or endogenous IL-8 are presented. Preferably, the recombinant IL-8 antibody or scFv fragment includes a Vsegment comprising a first amino acid sequence selected from SEQ ID NO. 1-15, 31-32, and/or a Vsegment comprising a second amino acid sequence selected from SEQ ID NO. 16-30, 33-34. The recombinant IL-8 antibody or scFv fragment can be formulated as pharmaceutical compositions to administer to a patient having a tumor to reduce metastasis of the tumor, reduce immune suppression in the tumor microenvironment or reduce Th2 mediated immune response.


Find Patent Forward Citations

Loading…